Article
Clinical utility of liquid biopsy for EGFR driver, T790M mutation and EGFR amplification in plasma in patients with acquired resistance to afatinib.
BMC cancer - 12 Jan 2021
Oya Yuko, Yoshida Tatsuya, Asada Kazuhiro, Oguri Tetsuya, Inui Naoki, Morikawa Sayako, Ito Kentaro, Kimura Tomoki, Kunii Eiji, Matsui Takashi, Kubo Akihito, Kato Tatsuo, Abe Takashi, Tsuda Takeshi, Hida Toyoaki
Abstract excerpt
BACKGROUND: Cell-free DNA (cfDNA) genotyping in plasma using the cobas EGFR Mutation Test v2 (cobas) is the first liquid biopsy as a companion diagnosis to identify the EGFR T790M mutation (T790M) after the failure of treatment of EGFR-tyrosine kinase inhibitors (TKIs) (1st generation, gefitinib [G] and erlotinib [E] and 2nd generation, afatinib [A]). This study investigated the clinical utility of a liquid...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.